science

Olokizumab

Olokizumab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Olokizumab rather than just read about it. In short: Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6).

Key takeaways

Olokizumab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Olokizumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Olokizumab from memory before moving on to harder problems.

Reference excerpt

Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. Olokizumab was developed by R-Pharm group, and was launched in 2020.

Medical uses

Rheumatoid arthritis Olokizumab was approved for medical use in Russia, Kazakhstan, Belarus, Kirgizstan and Azerbaijan under the brand name Artlegia for treatment of patients aged 18 years or older with moderate to severe rheumatoid arthritis in combination with methotrexate who have an inadequate response to methotrexate or tumor necrosis factor inhibitor (TNFi) therapy.

COVID-19 Olokizumab was approved for pathogenesis-based therapy of cytokine release syndrome in patients with moderate to severe new coronavirus infection (COVID-19) was approved in Russia, Kirgizstan and Azerbaijan.

Contraindications

A history of hypersensitivity to olokizumab or any component of the drug. Active infectious diseases (including tuberculosis). Children under 18 years of age. Hereditary fructose intolerance (the drug contains sorbitol). Breastfeeding

Drug interactions

In all clinical trials in patients with rheumatoid arthritis, olokizumab was used in conjunction with methotrexate. Special clinical studies of drug interactions of olokizumab have not been conducted. Concomitant use with methotrexate did not affect the olokizumab exposure. The effect of olokizumab on the methotrexate exposure is not expected with their simultaneous use. According to the results of the CREDO1–3 clinical trials, no cases of clinically significant drug interactions of olokizumab with other drugs were reported. In an in vitro study on human cryopreserved hepatocytes, olokizumab reversed the inhibitory effect of IL-6 on CYP1A1/2, 2B6, 2C9, 3A4/5 and 2C19 activity, as well as on NTCP activity. Thus, it should be considered that in patients with active rheumatoid arthritis, dose adjustment of drugs metabolized by these CYP isoforms may be necessary after beginning the treatment with olokizumab. The concentration of the following drugs may decrease when used together with olokizumab (including, but not limited to): statins (simvastatin, lovastatin, atorvastatin); oral contraceptives; calcium channel blockers; glucocorticoids (dexamethasone, methylprednisolone); warfarin; quinidine; theophylline; tizanidine; phenytoin; pimozide; cyclosporine; sirolimus; tacrolimus; benzodiazepines (e.g., diazepam, alprazolam, triazolam, midazolam, bromazepam).

History Olokizumab efficacy and safety were studied as part of a large-scale program of clinical trials, CREDO, which included 2,444 adult patients with rheumatoid arthritis from 19 countries worldwide. The study of olokizumab continues in the general, open-label, long-term extension. CREDO 1. Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy. CREDO 2. Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy. CREDO 3. Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy. CREDO 4. Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis.

References

External links

"Olokizumab". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on October 20, 2022.

Worked examples

Example 1 — a first encounter with Olokizumab

Start with the simplest possible case. Write down what Olokizumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Olokizumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Olokizumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Olokizumab

In research: Olokizumab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Olokizumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Olokizumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Olokizumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Olokizumab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Olokizumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Olokizumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Olokizumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Olokizumab in simple terms?

Why does Olokizumab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Olokizumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Olokizumab.